Psomagen

950200KOSDAQIndustrialsTrading normally
US$2.28
▲ +US$0.05 (+2.37%)Close · 2026-10-21
Share price
▼ −17.2%over 1y
25/1026/0126/0426/0726/10
$2.0$2.5$3.0

Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.

What the company does

Psomagen provides genomic sequencing and genetic analysis services, laboratory work that reads and interprets DNA to support research, diagnostics, and life-science applications.

Its services are used by researchers, healthcare institutions, and biotechnology companies. Listed on KOSDAQ, South Korea's technology and small-cap exchange, the company operates in a field where the underlying filing text does not specify a single dominant product line or structural shift.

Summary is AI-generated and may contain errors · figures from DART filings

KEY FACTS
Market capUS$43.8M
SectorIndustrials
SubsectorCommercial Services
MarketKOSDAQ
Cap tierSmall-cap
Financials
3Y · FY2023~2025 · USD · all filed years
Revenue
US$31.4KFY2025 · latest
'23'24'25
low US$18.7Khigh US$31.4K
Operating profit
−US$1.2KFY2025 · loss · latest
'23'24'25
low −US$2.9Khigh −US$1.2K
● red = loss year
Net income
−US$2.2KFY2025 · loss · latest
'23'24'25
low −US$3.4Khigh −US$2.2K
● red = loss year
Hover or tap a year for its figure · red dot = loss year · latest FY2025
Quick answers

Psomagen in five facts

What does Psomagen do?

Psomagen provides genomic sequencing and genetic analysis services, laboratory work that reads and interprets DNA to support research, diagnostics, and life-science applications.

Where is Psomagen listed and in which sector?

Psomagen (Korean name: 소마젠) trades under KRX code 950200 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.

How large is Psomagen?

Its market capitalisation was US$43.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).

What were Psomagen's latest annual revenue and operating profit?

For fiscal year 2025, Psomagen reported revenue of US$31.4K, an operating loss of US$1.2K and a net loss of US$2.2K, per its annual report on DART (data retrieved from DART on 2026-06-04). Revenue was up 30.0% on the previous year.

Where does this data come from?

Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.

Data sources

Data sources and last updated

Filings and financial statements
DART (dart.fss.or.kr), Korea's official corporate-filing system
Prices, market cap, trading status
KRX (Korea Exchange), via FinanceDataReader
Latest annual financials
Fiscal year 2025, data retrieved from DART on 2026-06-04
Share price and market cap
Close of 2026-10-21
Currency
US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
Company data updated
2026-10-21
Company summary
AI-generated from filings; may contain errors. Information only, not investment advice.